1. Home
  2. EXEL
  3. EXEL News

Latest Exelixis Inc. (EXEL) News on June 19, 2025

Zacks.com featured highlights include Flex, CVS Health, Urban Outfitters and Exelixis
EXEL

Zacks

6 days ago

Zacks.com featured highlights include Flex, CVS Health, Urban Outfitters and Exelixis

Why Is Exelixis (EXEL) Down 7.2% Since Last Earnings Report?
EXEL

Zacks

7 days ago

Why Is Exelixis (EXEL) Down 7.2% Since Last Earnings Report?

Can ‘reputational pull’ save biotech from pharma’s image problem?
EXEL

Pharma Voice

7 days ago

Can ‘reputational pull’ save biotech from pharma’s image problem?

3 Underfollowed Stocks on the Move Now (OLO, PLMR, EXEL)
EXEL

Zacks

8 days ago

3 Underfollowed Stocks on the Move Now (OLO, PLMR, EXEL)

EXEL

Argus Research

9 days ago

EXEL: What does Argus have to say about EXEL?

3 Reasons Why Growth Investors Shouldn't Overlook Exelixis (EXEL)
EXEL

Zacks

10 days ago

3 Reasons Why Growth Investors Shouldn't Overlook Exelixis (EXEL)

This IBD 50 Biotech's Got 'Rhythm' — And Flashes 3 Telltale Clues
EXEL

Investor's Business Daily

13 days ago

This IBD 50 Biotech's Got 'Rhythm' — And Flashes 3 Telltale Clues

Kymera Therapeutics Stock Earns 92 RS Rating
EXEL

Investor's Business Daily

13 days ago

Kymera Therapeutics Stock Earns 92 RS Rating

Are You Looking for a Top Momentum Pick? Why Exelixis (EXEL) is a Great Choice
EXEL

Zacks

13 days ago

Are You Looking for a Top Momentum Pick? Why Exelixis (EXEL) is a Great Choice

BofA Hikes Exelixis, Inc. (EXEL) Target Amid CRC Caution
EXEL

Insider Monkey

13 days ago

BofA Hikes Exelixis, Inc. (EXEL) Target Amid CRC Caution

Exelixis Stock Surges 28% YTD: Should You Buy Now or Sell?
EXEL

Zacks

15 days ago

Exelixis Stock Surges 28% YTD: Should You Buy Now or Sell?

Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term
EXEL

Zacks

15 days ago

Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term

Here's Why Exelixis (EXEL) is a Strong Growth Stock
EXEL

Zacks

17 days ago

Here's Why Exelixis (EXEL) is a Strong Growth Stock

Top 4 Value Stocks With Impressive PEG Ratios to Buy Now
EXEL

Zacks

20 days ago

Top 4 Value Stocks With Impressive PEG Ratios to Buy Now

2 Top Stocks to Buy With Less Than $100
EXEL

Motley Fool

20 days ago

2 Top Stocks to Buy With Less Than $100

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
EXEL

Zacks

22 days ago

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term

3 Reasons Why Growth Investors Shouldn't Overlook Exelixis (EXEL)
EXEL

Zacks

a month ago

3 Reasons Why Growth Investors Shouldn't Overlook Exelixis (EXEL)

Earnings Estimates Moving Higher for Exelixis (EXEL): Time to Buy?
EXEL

Zacks

a month ago

Earnings Estimates Moving Higher for Exelixis (EXEL): Time to Buy?

Exelixis (EXEL) Upgraded to Buy: What Does It Mean for the Stock?
EXEL

Zacks

a month ago

Exelixis (EXEL) Upgraded to Buy: What Does It Mean for the Stock?

EXEL vs. ARGX: Which Stock Is the Better Value Option?
EXEL

Zacks

a month ago

EXEL vs. ARGX: Which Stock Is the Better Value Option?

EXEL Reports Superior Efficacy Data From Kidney Cancer Study Cohort
EXEL

Zacks

a month ago

EXEL Reports Superior Efficacy Data From Kidney Cancer Study Cohort

Solid Earnings Reflect Exelixis' (NASDAQ:EXEL) Strength As A Business
EXEL

Simply Wall St.

a month ago

Solid Earnings Reflect Exelixis' (NASDAQ:EXEL) Strength As A Business

Product Performance, Big Money Lift Exelixis
EXEL

FX Empire

a month ago

Product Performance, Big Money Lift Exelixis

EXEL

MT Newswires

a month ago

Exelixis Insider Sold Shares Worth $1,515,091, According to a Recent SEC Filing

EXEL

MT Newswires

a month ago

Exelixis Reports 'Encouraging' Data in Kidney Cancer Trial

Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025
EXEL

Business Wire

a month ago

Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May and June
EXEL

Business Wire

a month ago

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May and June

Exelixis (NasdaqGS:EXEL) Reports Robust Q1 2025 Earnings and Revenue Growth
EXEL

Simply Wall St.

a month ago

Exelixis (NasdaqGS:EXEL) Reports Robust Q1 2025 Earnings and Revenue Growth

EXEL

Argus Research

a month ago

EXEL: Raising target price to $49.00

ACADIA Pharmaceuticals Stock Sees RS Rating Jump To 93
EXEL

Investor's Business Daily

a month ago

ACADIA Pharmaceuticals Stock Sees RS Rating Jump To 93

Exelixis (EXEL) is a Great Momentum Stock: Should You Buy?
EXEL

Zacks

a month ago

Exelixis (EXEL) is a Great Momentum Stock: Should You Buy?

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
EXEL

Zacks

a month ago

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Unlocking Exelixis (EXEL) International Revenues: Trends, Surprises, and Prospects
EXEL

Zacks

a month ago

Unlocking Exelixis (EXEL) International Revenues: Trends, Surprises, and Prospects

EXEL

MT Newswires

a month ago

Exelixis Insider Sold Shares Worth $4,600,000, According to a Recent SEC Filing

EXEL

MT Newswires

a month ago

Exelixis Insider Sold Shares Worth $1,619,130, According to a Recent SEC Filing

EXEL

MT Newswires

a month ago

Exelixis Insider Sold Shares Worth $1,154,500, According to a Recent SEC Filing

EXEL

MT Newswires

a month ago

Exelixis Insider Sold Shares Worth $6,488,503, According to a Recent SEC Filing

Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term
EXEL

Zacks

a month ago

Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term

Company News for May 15, 2025
EXEL

Zacks

a month ago

Company News for May 15, 2025

Why Exelixis, Inc. (EXEL) Skyrocketed On Wednesday
EXEL

Insider Monkey

a month ago

Why Exelixis, Inc. (EXEL) Skyrocketed On Wednesday

These Stocks Moved the Most Today: Nvidia, AMD, Super Micro, UnitedHealth, eToro, Oklo, Exelixis, and More
EXEL

Barrons.com

a month ago

These Stocks Moved the Most Today: Nvidia, AMD, Super Micro, UnitedHealth, eToro, Oklo, Exelixis, and More

eToro's Nasdaq debut, Exelixis outlook, Septerna–Novo deal
EXEL

Yahoo Finance Video

a month ago

eToro's Nasdaq debut, Exelixis outlook, Septerna–Novo deal

Why Exelixis Stock Is Skyrocketing Today
EXEL

Motley Fool

a month ago

Why Exelixis Stock Is Skyrocketing Today

EXEL Q1 Earnings Beat, 2025 Sales View Up as Cabometyx Drives Top Line
EXEL

Zacks

a month ago

EXEL Q1 Earnings Beat, 2025 Sales View Up as Cabometyx Drives Top Line

EXEL

Thomson Reuters StreetEvents

a month ago

Q1 2025 Exelixis Inc Earnings Call

These Stocks Are Moving the Most Today: Nvidia, AMD, Super Micro, UnitedHealth, American Eagle, Exelixis, Grail, and More
EXEL

Barrons.com

a month ago

These Stocks Are Moving the Most Today: Nvidia, AMD, Super Micro, UnitedHealth, American Eagle, Exelixis, Grail, and More

EXEL

MT Newswires

a month ago

Morgan Stanley Adjusts Price Target on Exelixis to $47 From $40, Maintains Overweight Rating

Exelixis Inc (EXEL) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
EXEL

GuruFocus.com

a month ago

Exelixis Inc (EXEL) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

Exelixis [NasdaqGS:EXEL] Sees US$555 Million Revenue With Earnings Up Sharply
EXEL

Simply Wall St.

a month ago

Exelixis [NasdaqGS:EXEL] Sees US$555 Million Revenue With Earnings Up Sharply

Exelixis (EXEL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
EXEL

Zacks

a month ago

Exelixis (EXEL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Exelixis (EXEL) Surpasses Q1 Earnings and Revenue Estimates
EXEL

Zacks

a month ago

Exelixis (EXEL) Surpasses Q1 Earnings and Revenue Estimates

EXEL

MT Newswires

a month ago

Exelixis Q1 Non-GAAP Earnings, Revenue Rise; 2025 Revenue Outlook Lifted -- Shares Up After Hours

Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?
EXEL

Zacks

a month ago

Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
EXEL

Zacks

a month ago

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Is Exelixis, Inc. (EXEL) One of the Best Stocks to Buy According to Jim Simons’ Renaissance Technologies?
EXEL

Insider Monkey

a month ago

Is Exelixis, Inc. (EXEL) One of the Best Stocks to Buy According to Jim Simons’ Renaissance Technologies?

Ahead of Exelixis (EXEL) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
EXEL

Zacks

a month ago

Ahead of Exelixis (EXEL) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May
EXEL

Business Wire

a month ago

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May

EXEL

Argus Research

a month ago

EXEL: Lowering target price to $40.00

Exelixis, Inc. (EXEL): Among the Large-Cap Stocks Insiders and Short Sellers Are Dumping Like Crazy
EXEL

Insider Monkey

2 months ago

Exelixis, Inc. (EXEL): Among the Large-Cap Stocks Insiders and Short Sellers Are Dumping Like Crazy

Here's Why Exelixis (EXEL) is a Strong Momentum Stock
EXEL

Zacks

2 months ago

Here's Why Exelixis (EXEL) is a Strong Momentum Stock

Exelixis to Release First Quarter 2025 Financial Results on Tuesday, May 13, 2025
EXEL

Business Wire

2 months ago

Exelixis to Release First Quarter 2025 Financial Results on Tuesday, May 13, 2025

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
EXEL

Zacks

2 months ago

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

MercadoLibre, The Amazon Of Latin America, Leads Five Stocks Near Buy Points
EXEL

Investor's Business Daily

2 months ago

MercadoLibre, The Amazon Of Latin America, Leads Five Stocks Near Buy Points

Exelixis' Q1 Earnings: Will Cabometyx Maintain Momentum?
EXEL

Zacks

2 months ago

Exelixis' Q1 Earnings: Will Cabometyx Maintain Momentum?

Earnings Preview: Alkermes (ALKS) Q1 Earnings Expected to Decline
EXEL

Zacks

2 months ago

Earnings Preview: Alkermes (ALKS) Q1 Earnings Expected to Decline

Here's Why Exelixis (EXEL) is a Strong Value Stock
EXEL

Zacks

2 months ago

Here's Why Exelixis (EXEL) is a Strong Value Stock

EXEL

Argus Research

2 months ago

EXEL: What does Argus have to say about EXEL?

Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Q1 Release
EXEL

Zacks

2 months ago

Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Q1 Release

High Growth Tech Stocks To Watch In The US April 2025
EXEL

Simply Wall St.

2 months ago

High Growth Tech Stocks To Watch In The US April 2025

Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term
EXEL

Zacks

2 months ago

Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term

EXEL

Argus Research

2 months ago

EXEL: Raising target price to $40.00

Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?
EXEL

Zacks

2 months ago

Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
EXEL

Zacks

2 months ago

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

EXEL

Argus Research

2 months ago

EXEL: Lowering target price to $37.00

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
EXEL

Zacks

2 months ago

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term

The Smartest Biotech Stocks to Buy With $50
EXEL

Motley Fool

3 months ago

The Smartest Biotech Stocks to Buy With $50

Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More
EXEL

Zacks

3 months ago

Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More

Is Exelixis, Inc. (EXEL) The Most Profitable Biotech Stock To Buy Right Now?
EXEL

Insider Monkey

3 months ago

Is Exelixis, Inc. (EXEL) The Most Profitable Biotech Stock To Buy Right Now?

EXEL

Argus Research

3 months ago

EXEL: Lowering target price to $40.00

FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors
EXEL

Zacks

3 months ago

FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors

Exelixis’ cabozantinib approval ‘certainly positive,’ says Citi
EXEL

TipRanks

3 months ago

Exelixis’ cabozantinib approval ‘certainly positive,’ says Citi

Exelixis to present positive preclinical data across pipeline portfolio at AACR
EXEL

TipRanks

3 months ago

Exelixis to present positive preclinical data across pipeline portfolio at AACR

Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold?
EXEL

Zacks

3 months ago

Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold?

Exelixis (NasdaqGS:EXEL) Celebrates FDA Approval For Expanded CABOMETYX® Use In Treating NET
EXEL

Simply Wall St.

3 months ago

Exelixis (NasdaqGS:EXEL) Celebrates FDA Approval For Expanded CABOMETYX® Use In Treating NET

EXEL

MT Newswires

3 months ago

Exelixis Gets FDA Approval for Drug Treating Patients With Previously Treated Advanced Neuroendocrine Tumors

Here's Why Exelixis (EXEL) is a Strong Growth Stock
EXEL

Zacks

3 months ago

Here's Why Exelixis (EXEL) is a Strong Growth Stock

Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
EXEL

Business Wire

3 months ago

Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

EXEL

Argus Research

3 months ago

EXEL: Raising target price to $41.00

Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025
EXEL

Business Wire

3 months ago

Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025

Biotech Leader Exelixis Eyes Buy Point In Monday's Stock Market Rally
EXEL

Investor's Business Daily

3 months ago

Biotech Leader Exelixis Eyes Buy Point In Monday's Stock Market Rally

Exact Sciences (EXAS) Down 10.6% Since Last Earnings Report: Can It Rebound?
EXEL

Zacks

3 months ago

Exact Sciences (EXAS) Down 10.6% Since Last Earnings Report: Can It Rebound?

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
EXEL

Zacks

3 months ago

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Exelixis Growth Continues with Big Money Boosts
EXEL

FX Empire

3 months ago

Exelixis Growth Continues with Big Money Boosts

Exelixis, Inc. (EXEL): Among the Best Biotech Stocks to Buy According to Billionaires
EXEL

Insider Monkey

3 months ago

Exelixis, Inc. (EXEL): Among the Best Biotech Stocks to Buy According to Billionaires

Exelixis (EXEL) Up 13.4% Since Last Earnings Report: Can It Continue?
EXEL

Zacks

3 months ago

Exelixis (EXEL) Up 13.4% Since Last Earnings Report: Can It Continue?

EXEL

MT Newswires

3 months ago

RBC Raises Price Target on Exelixis to $40 From $38, Keeps Outperform Rating

EXEL vs. ARGX: Which Stock Should Value Investors Buy Now?
EXEL

Zacks

3 months ago

EXEL vs. ARGX: Which Stock Should Value Investors Buy Now?

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
EXEL

Zacks

3 months ago

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

EXEL

Argus Research

4 months ago

EXEL: Raising target price to $42.00

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
EXEL

Zacks

4 months ago

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Share on Social Networks: